MEDDDICAL newsarticles

MEDDDICAL Expands RWD Advisory & Strategic Data Analytics For MedTech Firms

Mon, 17 Aug 2026 07:50:24 -0700

MEDDDICAL now provides strategic advisory services for MedTech organizations developing real-world evidence (RWE) programs, introducing a structured approach that helps teams establish evidence requirements before evaluating health data providers. The service helps pharmaceutical and MedTech organizations align data partnerships with clinical, commercial, and market access objectives before significant resources are committed.

More information is available at https://medddical.com/

Real-world evidence continues to play a growing role in regulatory submissions, market access, health economics, and commercial decision-making. According to IQVIA, the volume and diversity of available real-world health data have expanded rapidly in recent years, giving life sciences organizations unprecedented access to patient-level insights. As the number of datasets, analytical platforms, and specialist providers continues to grow, the challenge has shifted from finding data to determining which evidence strategy best supports a program's objectives.

MEDDDICAL notes that one of the most expensive decisions in an evidence program often occurs before a dataset is ever licensed. Many organizations begin comparing vendors before clearly defining the business question they need the evidence to answer. Without established requirements, it becomes difficult to determine which combination of claims data, study design, analytical methods, and compliance capabilities best supports the program's objectives, increasing the risk of unnecessary expenditure and evidence that falls short of strategic needs.

"Successful evidence programs begin with a clearly defined question, not a vendor comparison," a MEDDDICAL spokesperson said. "Once the objectives are established, evaluating data partners becomes a strategic exercise focused on identifying the capabilities that best support those goals."

Building on that principle, MEDDDICAL helps MedTech organizations define evidence requirements before evaluating data partners, compliance considerations, and analytical approaches. The company acts as an independent strategic advisor throughout the planning process, helping clients assess which data sources, analytical approaches, and health insurance data partnerships are most appropriate for their specific commercial, clinical, or reimbursement objectives.

About MEDDDICAL

MEDDDICAL advisors support pharmaceutical and MedTech organizations in health market intelligence and real-world evidence. The multidisciplinary team combines expertise in health economics, statistics, and data science to help clients evaluate evidence strategies and connect with qualified health insurance data partners across Europe and globally.

Additional information is available at https://medddical.com/

Company: MEDDDICAL City: Sotogrande Address: Aptos 221 Website: https://medddical.com

MEDDDICAL Announces RWE Strategy Advisory for Biotech Clinical Development

Sun, 19 Jul 2026 23:52:04 -0700

MEDDDICAL has announced the launch of a real-world evidence (RWE) advisory service for pharmaceutical and biotech teams seeking clearer data strategy, predictive intelligence, and market access support during increasingly compressed development cycles.

More information is available at https://medddical.com/services/

The service is designed for teams working across claims data strategy, synthetic patient cohort evaluation, AI-powered analytics, and RWE-informed market access planning, helping companies decide which data sources, analytical frameworks, and evidence-generation approaches are credible enough to support development, payer, and regulatory decisions.

The launch comes as AI-assisted drug discovery continues to compress early research timelines. In “Accelerating Drug Development with AI in the U.S. Pharmaceutical Industry,” Intuition Labs cites the Exscientia and Sumitomo Dainippon Pharma DSP-1181 program, where an AI-designed OCD drug candidate entered clinical trials after 12 months, compared with the usual five years. Pharmaphorum also reported on January 30, 2020, that the program identified a candidate from roughly 350 synthesized compounds, compared with a typical 2,500.

The ongoing evolution of AI-assisted tools has had impacts on every aspect of the clinical development timeline, from patient selection to iterative chemistry and beyond, according to the 2024 NIH-indexed review “Artificial Intelligence (AI) Applications in Drug Discovery and Drug Development.” However, this accelerated pace has brought with it new challenges. Fortrea’s November 27, 2025, article, “Six challenges facing emerging biotechs and how to solve them,” identifies regulatory complexity, clinical risk, access to capital, vendor management, multinational trial management, and visibility as key issues for emerging biotech companies.

Those challenges can become more pronounced when biotech companies run up against a regulatory landscape still adapting to AI-assisted development timelines. A recent Pharmaceutical Technology article points to federal-level regulatory uncertainty in the US and outdated guidance as points of concern. In that coverage, Dr. Rachel Salzman, CEO of Armatus Bio, discussed how uncertainty may influence where biotech companies and researchers choose to advance development work.

This pressure is underscored by a growing demand for RWE at all stages of development, particularly at the inception of a new project. Dr. David C. Klonoff of the Diabetes Research Institute has written that wearable devices and smartphones generate billions of user-specific data points every day, while AI can help researchers process large-scale real-world data and derive higher-quality evidence from it at an increased pace.

These findings could bring about a significant shift in how biotech projects are researched, funded, and progressed to market. In the meantime, emerging industry voices like MEDDDICAL will continue to help guide the future of RWE adoption.

“AI can accelerate discovery, but faster timelines only increase the need for stronger evidence strategy,” a MEDDDICAL spokesperson said. “Our advisory service helps pharma and biotech teams evaluate RWE options early, avoid poor data-fit decisions, and build evidence plans that can support development, access, and commercial strategy.”

About MEDDDICAL

MEDDDICAL is a comprehensive RWE advisory service operating at the intersection of intelligent technology and clinical best practices. Leaning on 13 years of industry experience, the advisory advocates for RWE strategies that orient client businesses toward the future of data collection and analysis.

Additional details can be found at https://medddical.com/

Company: MEDDDICAL City: Sotogrande Address: Aptos 221 Website: https://medddical.com

AI Synthetic Health Data Guide for Pharma Released: GAN, Privacy & Regulatory

Sun, 21 Jun 2026 23:19:26 -0700

"The conversation around synthetic health data in pharma is frequently either oversold or dismissed," said the team at MEDDDICAL. "Neither position is analytically defensible. There is a precise set of use cases where AI-generated synthetic data outperforms any alternative — rare disease augmentation, cross-border GDPR-compliant data integration, synthetic data in machine learning for medicine and healthcare, and ML training pipelines chief among them. There is an equally precise set of use cases where it should not be used, including primary causal inference for regulatory submissions. The guide draws those boundaries with technical precision."

Debunking the "Made-Up Data" Objection

The guide opens with a direct treatment of the objection most commonly encountered in pharmaceutical settings: that synthetic health data is simply invented and therefore analytically worthless. The firm argues this framing conflates high-fidelity GAN-generated synthetic data — which encodes the statistical structure of real patient populations without containing any real patient's record — with fabricated data.

The guide explains that a synthetic EHR dataset — including synthetic patient records — and high-fidelity synthetic medical data generated by a properly trained and validated generative model encodes genuine epidemiological structure: realistic comorbidity co-occurrence, plausible treatment sequences, age-stratified disease prevalence, and temporal patterns of healthcare utilisation. The privacy protection is structural rather than procedural — the synthetic dataset contains no real records to re-identify.

GAN Architecture and Healthcare-Specific Requirements

The guide provides a detailed treatment of Generative Adversarial Network architectures and their healthcare-specific variants, including medGAN, RGAN, CTGAN, and DP-GAN. Particular attention is paid to temporal modelling requirements for longitudinal EHR data, and to the critical failure mode of mode collapse — a condition where the generator under-represents rare patient subpopulations, which is especially problematic in rare disease contexts.

Differential Privacy: The Mathematical Privacy Guarantee

A substantial section addresses differential privacy, synthetic healthcare data and synthetic healthcare data platform selection criteria, and the synthetic data generation healthcare teams must understand before selecting a synthetic data generator healthcare vendors provide and its implementation through Differentially Private Stochastic Gradient Descent (DP-SGD). The guide provides practical guidance on epsilon (ε) parameter selection, explaining the privacy-utility trade-off at different values and the conditions under which specific ε ranges are appropriate for healthcare applications. The guide states clearly that ε selection requires a documented privacy impact assessment and should not be treated as a purely technical parameter.

Validation Methodology

The guide introduces a three-dimension validation framework requiring assessment of statistical fidelity, analytical utility, and privacy in all validated synthetic datasets. Key metrics are specified with target thresholds: Jensen-Shannon divergence below 0.05 per variable for univariate fidelity; discriminator AUC below 0.60 for multivariate indistinguishability; and the Train-on-Synthetic, Test-on-Real (TSTR) paradigm for utility assessment. The guide emphasises that validation is use-case specific — a dataset validated for ML model training is not automatically validated for RWE support analytics.

Use Case Mapping: Where Synthetic Data Wins and Where It Doesn't

The guide provides explicit use case mapping, covering where a synthetic healthcare database is appropriate, identifying rare disease data augmentation, cross-border GDPR-compliant data sharing, and ML training pipelines as the strongest current use cases. It identifies primary causal inference for regulatory submissions, pharmacovigilance signal detection, and absolute event rate estimation as use cases where synthetic data is currently inappropriate or insufficient.

On cross-border data sharing, the guide notes that the GDPR challenge for multi-country European RWE studies is a structural problem that synthetic data addresses more cleanly than alternative approaches: synthetic data generated at each national site contains no real patient records and can therefore be legally combined across borders without triggering data transfer restrictions.

Regulatory Acceptance: Where the Ceiling Currently Sits

The guide addresses regulatory acceptance with what the firm describes as a precise rather than optimistic framing. Synthetic data healthcare applications are mapped against current regulatory positions with specificity. As of 2026, no major regulatory agency permits AI-generated synthetic health data as the primary evidence source for a regulatory submission. The FDA's most advanced acceptance is in the medical device pathway under CDRH, where synthetic data is explicitly permitted as training and testing data for AI/ML-based medical devices. For drug development, acceptance extends to trial simulation, sensitivity analysis augmentation, and rare disease external control arm contexts.

The guide acknowledges that the regulatory ceiling is not static, citing the EMA's DARWIN EU programme and ongoing FDA engagement with synthetic control arm approaches in rare disease as indicators of an evolving position.

Implementation Framework

The guide concludes with a four-section implementation checklist covering use case definition, data architecture and generation, three-dimension validation, and governance and regulatory documentation — providing a practical framework for pharmaceutical organisations initiating or expanding their use of synthetic health data.

The guide is the fourth publication in MEDDDICAL's RWD Medical Series and the first dedicated to synthetic healthcare data, following guides on phenotype validation in real-world data studies, longitudinal data requirements for RWE, and predictive modelling in healthcare.

About MEDDDICAL

MEDDDICAL is a Pan-European Real-World Evidence advisory service helping pharmaceutical and MedTech organisations navigate the real-world data landscape. MEDDDICAL provides expert guidance on RWE strategy, data source evaluation, vendor selection, and synthetic data strategy across Continental European markets.

Contact: https://medddical.com/contact/

Guide URL: https://synthetichealthdata.medddical.com

Company: MEDDDICAL City: Sotogrande Address: Aptos 221 Website: https://medddical.com

MEDDDICAL Expands Focus On Real-World Evidence Strategy For Pharma & MedTech

Wed, 17 Jun 2026 23:13:56 -0700

While large volumes of real-world data (RWD) are now available, pharmaceutical R&D and market access teams often struggle with aligning analytical methods, data sources, and compliance expectations across different jurisdictions. This disconnect can slow clinical development timelines and affect the efficiency of evidence generation programs. To address this gap, MEDDDICAL has launched an advisory service focused on helping organizations structure and apply real-world data strategies more effectively across clinical development and market access workflows.

More details can be found at https://medddical.com/

The increasing reliance on RWD and RWE reflects a broader shift in how healthcare evidence is evaluated globally. According to the UC Berkeley School of Public Health, more effective use of real-world data may support faster and more efficient clinical trials, particularly when integrated with traditional study designs. At the same time, regulatory agencies are formalizing pathways for its use.

The U.S. Food and Drug Administration (FDA) issued updated draft guidance in 2024 for drugs and biologics, followed by 2025 guidance for medical devices, recognizing electronic health records and claims data as valid scientific evidence when appropriately analyzed. In Europe and the UK, the European Medicines Agency’s DARWIN EU initiative and the National Institute for Health and Care Excellence (NICE) have similarly expanded frameworks for incorporating RWE into regulatory and reimbursement decisions.

Despite this progress, pharmaceutical organizations continue to face fragmentation across global regulatory systems, with differing standards for data quality, methodology, and acceptance criteria. This complexity can lead to inefficiencies when companies engage multiple data vendors without clearly defined analytical and regulatory requirements, increasing the risk of misaligned study design and delayed submissions.

Within this context, new advisory models focused on early-stage strategy and requirements definition are being used in response to these structural challenges in the RWE ecosystem. MEDDDICAL's approach centers on supporting organizations in clarifying their evidence-generation needs prior to vendor selection, with the aim of reducing iteration cycles in study design and improving alignment with regulatory expectations.

More broadly, the growing use of real-world data in regulatory and reimbursement decision-making is reshaping how evidence is planned and evaluated in drug development. As datasets become more diverse and global regulatory expectations remain inconsistent, greater emphasis is being placed on early decisions around study design, data suitability, and methodological standards to reduce downstream inefficiencies.

About MEDDDICAL

MEDDDICAL is an independent advisory focused on real-world evidence (RWE) strategy for life sciences organizations. The consultancy supports pharmaceutical and MedTech teams in evaluating data requirements, study design considerations, and regulatory alignment needs across clinical development and market access programs.

Additional information is available at https://medddical.com

Company: MEDDDICAL City: Sotogrande Address: Aptos 221 Website: https://medddical.com

Outcome Prediction Models in Healthcare: RWD Predictive Analytics Guide Released

Sun, 14 Jun 2026 07:48:34 -0700

MEDDDICAL has released a guide addressing one of the most consistently underestimated challenges in pharmaceutical predictive analytics: the gap between having access to real-world claims data and having a dataset that is actually suitable for training outcome prediction models. The guide provides pharma data scientists, RWE Directors, and commercial analytics teams with a practical framework for dataset evaluation, validation design, and synthetic data use — covering the three primary applications of predictive modelling in pharmaceutical research: patient stratification, treatment response prediction, and commercial forecasting.

More details can be found at https://medddical.com/real-world-evidence-strategy-and-analytics/outcome-prediction-models-healthcare-rwd-predictive-analytics/

Predictive modelling with real-world data has become a strategic priority across the pharmaceutical industry, as companies seek to optimise clinical development pipelines, support market access negotiations, and improve commercial forecast accuracy through data-driven approaches. Yet the majority of predictive modelling programmes built on claims data encounter avoidable failures — not because the modelling methodology is wrong, but because the training dataset was not evaluated rigorously enough before model development began. Feature completeness was assumed rather than verified. Outcome labelling quality was taken on trust rather than validated against clinical records. Data leakage risk was not assessed before training, inflating internal validation metrics in ways that only became visible at deployment.

The guide addresses dataset suitability criteria that are specific to predictive model training rather than descriptive epidemiology. For each of the three primary use cases, MEDDDICAL's framework specifies the data characteristics that determine whether a claims dataset is fit for that analytical purpose, including feature completeness requirements, outcome labelling standards, temporal structure considerations, and population representativeness criteria across Continental European markets. The framework also covers two areas that standard data quality assessments consistently miss: the distinction between clinically significant missingness and administrative data gaps — which require fundamentally different imputation approaches — and the AI-readiness requirements that go beyond conventional data quality standards, including deep provenance tracking and systematic bias detection across payer environments and geographic markets.

Validation framework design is a central focus of the guide, given that internal validation — splitting the training dataset into training and test sets — is insufficient for models intended to support regulatory submissions or market access negotiations. The guide defines a four-level validation hierarchy covering internal, temporal, external, and clinical validation, and specifies the performance metrics appropriate for each application context. The TRIPOD and TRIPOD+AI reporting standards, along with FDA guidance on artificial intelligence and machine learning in regulatory applications, provide the framework against which model development and reporting should be structured.

The guide also provides a clear-eyed assessment of synthetic data use in pharmaceutical predictive modelling: where it genuinely helps — rare outcome augmentation, algorithm development under GDPR Article 9 constraints, commercial scenario modelling — and where it creates risk that most vendor conversations understate. Neither FDA nor EMA currently accepts synthetic data as the primary evidence base for predictive model validation in regulatory submissions, and the guide clarifies the specific technical limitations, particularly around model calibration, that make synthetic-data-primary training inadequate for clinical prediction applications.

The full methodological treatment, including the dataset evaluation checklist for pre-training assessment, is covered in MEDDDICAL's post on outcome prediction models in healthcare: using RWD to build predictive analytics.

For more information, visit https://predictivemodeling.medddical.com

---

ABOUT MEDDDICAL

MEDDDICAL is a Pan-European Real-World Evidence advisory service helping pharmaceutical and MedTech organisations navigate the real-world data landscape. MEDDDICAL provides expert guidance on RWE strategy, data source evaluation, and vendor selection across Continental European markets, connecting organisations with the right data partnerships for their specific use cases through expert-led consultation.

Contact: https://medddical.com/contact/

Company: MEDDDICAL City: Sotogrande Address: Aptos 221 Website: https://medddical.com

Longitudinal Data Analysis in Pharma: Dataset Requirements Guide Released

Sun, 24 May 2026 11:15:05 -0700

MEDDDICAL has released a guide addressing a critical gap in pharmaceutical Real-World Evidence: how to evaluate and specify longitudinal data requirements before engaging vendors. The guide provides RWE Directors with actionable methodology for defining what constitutes a fit-for-purpose dataset, directly tackling the frequent mismatch between what companies request and what data providers actually deliver. Rather than offering generic best practices, the resource focuses on concrete specifications that can be applied immediately to vendor conversations and data procurement processes.

More details can be found at https://medddical.com/real-world-evidence-strategy-and-analytics/longitudinal-data-analysis-pharma-dataset-fit-for-purpose/

The stakes for getting longitudinal data specifications right have never been higher. FDA inspection data reveals a 43% increase in warning letter rates between 2019 and 2023, with data integrity issues representing a consistent category of violations. In a widely cited 2019 case, US-based pharma company Zogenix received an FDA refusal-to-file letter for its seizure-control drug, a rejection that triggered a share price fall of nearly 23%, with the FDA citing, among other issues, the submission of an incorrect version of a clinical dataset. The case illustrates how data handling failures can contribute to regulatory rejection with direct financial consequences. For RWE Directors working with observational data, clarity around longitudinal dataset requirements has shifted from a technical preference to a risk-mitigation imperative.

Among the methodological gaps the guide addresses, index date definition stands out as both critical and commonly misunderstood. Simulation studies demonstrate that different time-zero settings can introduce significant bias, producing contradictory conclusions even when the same dataset is analysed for identical research questions. Because this bias compounds throughout the analysis if not addressed upfront, the guide provides RWE Directors with specific language for articulating index date parameters during initial vendor discussions, preventing the costly rework and analytical dead ends that vague specifications routinely produce.

Attrition and censoring schemes represent another area where imprecise requirements lead to regulatory failure. Research shows that inappropriate censoring can substantially bias median survival estimates, while data missingness remains a recurring cause of RWE submission rejection by both FDA and EMA. The guide provides concrete language for specifying attrition handling and censoring requirements before procurement begins, ensuring that the dataset contracted aligns with analytical needs rather than forcing retrospective compromises that undermine study validity.

Understanding what longitudinal depth actually means when evaluating a data source forms a central framework within the guide. Many adverse drug reactions and long-term health consequences manifest years or decades after initial exposure, requiring true continuity of patient observation rather than fragmented follow-up periods. European registries and health insurance claims databases can enable patient follow-up of ten years or longer, but vendor claims about longitudinal coverage vary widely in what they actually deliver at the level of coding completeness, attrition rates, and data continuity. The guide defines minimum follow-up periods and data continuity standards that distinguish genuine longitudinal capability from superficial claims, equipping RWE Directors to evaluate vendor offerings with precision rather than relying on headline coverage figures.

Taken together, the guide gives RWE Directors four things they can use immediately: a specification framework for minimum follow-up periods, concrete requirements language for attrition and censoring handling, a structured approach to index date definition that can be dropped into vendor briefs, and a set of evaluation criteria for assessing longitudinal depth claims.

Organisations that apply these specifications before entering vendor negotiations eliminate the most common sources of mismatch that delay studies, inflate costs, and in some cases produce the kind of regulatory consequences that no amount of analytical sophistication can recover from.

The full methodological treatment, including index date methodology, attrition handling approaches, and a vendor communication framework, is covered in MEDDDICAL's post on longitudinal data analysis in pharma: what makes a dataset fit for purpose.

For more information, visit https://longitudinaldata.medddical.com

---

ABOUT MEDDDICAL

MEDDDICAL is a Pan-European Real-World Evidence advisory service helping pharmaceutical and MedTech organisations navigate the real-world data landscape. MEDDDICAL provides expert guidance on RWE strategy, data source evaluation, and vendor selection across Continental European markets, connecting organisations with the right data partnerships for their specific use cases through expert-led consultation.

Contact: https://medddical.com/contact/

Company: MEDDDICAL City: Sotogrande Address: Aptos 221 Website: https://medddical.com

Phenotype Validation in Real-World Data Studies - Expert Guide Released

Thu, 21 May 2026 05:19:23 -0700

MEDDDICAL has released a guide addressing phenotype misclassification bias, a common source of error in observational Real-World Evidence (RWE). The guide provides methodological guidance on building and validating phenotype algorithms in claims data, including validation against gold-standard clinical records—a process that requires resource-intensive manual review by expert clinicians. The guide addresses a gap where many RWE teams underinvest, despite measurable impact on study accuracy and regulatory credibility.

More details can be found at https://medddical.com

The lack of standardization in phenotype algorithms has created a credibility challenge across the RWE landscape. Regulatory bodies including the FDA and EMA increasingly demand transparent, methodologically rigorous evidence submissions with computable phenotypes that enable replicable cohort selection and outcome determination. Academic studies have quantified the impact of misclassification, reporting statistically significant differences when self-reported data proved less accurate than coded diagnoses in electronic medical records.

The guide details how phenotype algorithms are constructed in administrative datasets and how they are validated against reference-standard clinical documentation. Validation requires expert clinical review of individual patient records to assess whether a phenotype definition correctly identifies individuals with and without a specific condition. High-quality phenotype definitions are necessary for regulatory submission and replicable cohort selection. The guide positions phenotype methodology as deserving the same rigor as statistical analysis, particularly given the scrutiny RWE now faces from regulators and payers.

MEDDDICAL advises pharmaceutical and MedTech companies on RWE strategy and analytics, offering independent guidance on data strategy, administrative datasets, synthetic cohorts, and AI-powered analytics. MEDDDICAL identifies material analytical risks in phenotype definition as a key focus area, reflecting its advisory experience in helping organizations ensure their evidence withstands regulatory and payer scrutiny. This guide reflects the strategic insights MEDDDICAL brings to independent RWE guidance, emphasizing that most teams underinvest in phenotype methodology relative to downstream analysis—often the stage where significant analytical risks emerge.

The guide equips RWE teams to strengthen their phenotype definitions and validation processes, directly supporting the transparency and methodological rigor that regulatory bodies now require. By addressing a common gap in evidence generation workflows, the resource enables more defensible, replicable, and credible RWE outputs. Teams building or validating phenotype algorithms can use the guide to operationalize better practices within their organizations, reducing phenotype-related analytical risk and improving the quality of their evidence base.

RWE Directors can access the guide and learn more about MEDDDICAL's advisory services at https://medddical.com. As the RWE landscape continues to evolve, phenotype rigor will remain a foundational requirement for evidence that meets the standards of regulators, payers, and clinical decision-makers.

Company: MEDDDICAL City: Sotogrande Address: Aptos 221 Website: https://medddical.com

MEDDDICAL Launches Insurance Claims Data & RWD Advisory Services for Pharma

Tue, 19 May 2026 12:36:32 -0700

As pharmaceutical companies face increasing pressure to demonstrate product value in real-world settings, MEDDDICAL has launched a new advisory service focused on helping pharmaceutical and MedTech companies use insurance claims data and real-world evidence more strategically across development, market access, and commercialization. The service is designed for organizations evaluating healthcare datasets, claims analytics, and patient-level real-world data to support decision-making throughout the product lifecycle.

More information is available at https://medddical.com

According to Deloitte, nearly 70% of pharmaceutical executives said improving access to external real-world data sources and analytics is now a high strategic priority for commercial and development planning. Insurance claims datasets and healthcare databases are increasingly being used to evaluate treatment pathways, patient outcomes, healthcare utilization, and reimbursement trends outside traditional clinical trial settings.

At the same time, many organizations struggle to navigate the growing number of healthcare database providers, analytics platforms, and overlapping data vendors entering the market. The new advisory service from MEDDDICAL focuses on helping clients define their requirements before committing to large-scale licensing agreements, analytics investments, or long-term vendor partnerships. That process may include evaluating all payer claims databases, DRG claims data, longitudinal patient datasets, and broader pharma real-world data ecosystems tied to commercial analytics and evidence generation.

In addition, the service supports pharmaceutical and medtech teams exploring synthetic patient cohorts, patient journey mapping, competitive intelligence initiatives, and AI-driven analytics connected to market access and commercialization planning. According to MEDDDICAL, many internal teams have strong expertise in either clinical development or data analysis, but not always both. The company says its role is to help bridge that gap by aligning scientific goals, operational priorities, and compliance considerations before major investments are made.

Real-world evidence and claims-based analytics continue playing a larger role in how pharmaceutical and medtech organizations evaluate treatment effectiveness, understand payer behavior, and identify unmet needs across patient populations. The company's advisory approach is intended to help clients move from fragmented data exploration toward clearer evidence strategies that support both development and commercial objectives.

About MEDDDICAL

MEDDDICAL is an independent advisory service focused on real-world evidence (RWE) strategy for life sciences organizations. The company supports pharmaceutical and MedTech teams in evaluating data requirements, study design considerations, and regulatory alignment needs across clinical development and market access programs.

For more information, visit https://medddical.com/services/

Company: MEDDDICAL City: Sotogrande Address: Aptos 221 Website: https://medddical.com

MEDDDICAL Launches Real-World Evidence Strategy & Analytics For Pharma & MedTech

Tue, 14 Apr 2026 23:45:09 -0700

MEDDDICAL has launched a real-world evidence analytics and advisory service, offering structured guidance to pharmaceutical and MedTech companies at a time when real-world evidence requirements from regulators and payers are growing more demanding across global drug development programs.

More information is available at https://medddical.com/

According to a 2024 IQVIA report, the volume of available real-world health data has grown considerably, yet many pharmaceutical organizations still face challenges in turning that data into evidence that can stand up to regulatory or payer scrutiny. The central issue is rarely a lack of data; more often, it is the difficulty of determining which sources, analytical frameworks, and compliance structures fit a program’s requirements before significant resources are committed.

That is the gap MEDDDICAL aims to address. The team provides independent advisory support across insurance claims data strategy, synthetic patient cohort design, AI-powered analytics guidance, and market access strategy consulting. Operating outside the vendor ecosystem, its recommendations are shaped by client needs rather than provider incentives.

A MEDDDICAL spokesperson said that many organizations begin evaluating vendors before clearly defining the underlying requirements of their program, including the level of data coverage, analytical methodology, and compliance structure needed. “That sequencing problem is where timelines collapse, and budgets get misallocated,” the spokesperson said. “Defining requirements first means every subsequent data decision rests on a clear foundation rather than assumptions.”

This approach becomes especially important in areas such as HEOR evidence development, loss-of-exclusivity forecasting, patient journey analysis, and AI-driven commercial sizing, where alignment between a program’s needs and a vendor’s actual capabilities can significantly affect timelines, budget efficiency, and decision quality, the team explains.

Most teams know they need European claims data, multi-country RWE, or GDPR-compliant data partnerships — but determining which combination of data sources, providers, and study designs actually fit their strategic objectives requires a level of market knowledge that internal teams rarely have bandwidth to build. MEDDDICAL operates as a neutral advisory layer between qualified organisations and health insurance data access partners across Europe and globally — handling the strategic evaluation, compliance navigation, and use-case alignment so that evidence teams can move faster and smarter, without over-committing to the wrong data relationship.

About MEDDDICAL

MEDDDICAL, which was founded on the belief that clearer evidence-based decisions lead to better patient outcomes, provides pharmaceutical and MedTech organizations with independent guidance in a data environment where poor choices can result in lost time and missed opportunities.

Further company information is available at https://medddical.com/

Company: MEDDDICAL City: Sotogrande Address: Aptos 221 Website: https://medddical.com